Cancer Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
home > drugs a-z list > navelbine (vinorelbine tartrate) drug center > navelbine (vinorelbine tartrate) drug - side effects and drug interactions
Recommended Topic Related To:
Navelbine
What is cancer?
Cancer is the uncontrolled growth of abnormal cells anywhere in a body. The abnormal cells are termed cancer cells, malignant cells, or tumor cells. Many cancers and the abnormal cells that compose the cancer tissue are further identified by the name of the tissue that the abnormal cells originated from (for example, breast cancer, lung cancer, colon cancer). Cancer is not confined to humans; animals and other living organisms can get cancer. Below is a schematic that shows normal cell division and how when a cell is damaged or altered without repair to its system, the cell usually dies. Also shown is what can occur when such damaged or unrepaired cells do not die and become cancer cells and proliferate with uncontrolled growth; a mass of cancer cells develop. Frequently, cancer cells can break away from this original mass of cells, travel through the blood and lymph systems, and lodge in other organs where they can again repeat the ...
Navelbine
|
|
SIDE EFFECTS
The pattern of adverse reactions is similar whether NAVELBINE (vinorelbine tartrate) is used as a single agent or in combination. Adverse reactions from studies with single-agent and combination use of NAVELBINE (vinorelbine tartrate) are summarized in Tables 2-4.
Single-Agent NAVELBINE (vinorelbine tartrate) : Data in the following table are based on the experience of 365 patients (143 patients with NSCLC; 222 patients with advanced breast cancer) treated with IV NAVELBINE (vinorelbine tartrate) as a single agent in 3 clinical studies. The dosing schedule in each study was 30 mg/m2 NAVELBINE (vinorelbine tartrate) on a weekly basis.
Table 2: Summary of Adverse Events in 365 Patients Receiving
Single-Agent NAVELBINE (vinorelbine tartrate) *†
| Adverse Event | All Patients (n=365) |
NSCLC (n=143) |
||||
| Bone Marrow | ||||||
| Granulocytopenia | <2,000 cells/mm3 | 90% | 80% | |||
| <500 cells/mm3 | 36% | 29% | ||||
| Leukopenia | <4,000 celIs/mm3 | 92% | 81% | |||
| <1,000 cells/mm3 | 15% | 12% | ||||
| Thrombocytopenia | <100,000 cells/mm3 | 5% | 4% | |||
| <50,000 cells/mm3 | 1% | 1% | ||||
| Anemia | <11 g/dL | 83% | 77% | |||
| <8 g/dL | 9% | 1% | ||||
| Hospitalizations due to granulocytopenic complications | 9% | 8% | ||||
| Adverse Event | All Grades | Grade 3 | Grade4 | |||
| All Patients | NSCLC | All Patients | NSCLC | All Patients | NSCLC | |
| Clinical Chemistry Elevations | ||||||
| Total Bilirubin (n=351) | 13% | 9% | 4% | 3% | 3% | 2% |
| SGOT (n=346) | 67% | 54% | 5% | 2% | 1% | 1% |
| General | ||||||
| Asthenia | 36% | 27% | 7% | 5% | 0% | 0% |
| Injection Site Reactions | 28% | 38% | 2% | 5% | 0% | 0% |
| Injection Site Pain | 16% | 13% | 2% | 1% | 0% | 0% |
| Phlebitis | 7% | 10% | <1% | 1% | 0% | 0% |
| Digestive | ||||||
| Nausea | 44% | 34% | 2% | 1% | 0% | 0% |
| Vomiting | 20% | 15% | 2% | 1% | 0% | 0% |
| Constipation | 35% | 29% | 3% | 2% | 0% | 0% |
| Diarrhea | 17% | 13% | 1% | 1% | 0% | 0% |
| Peripheral Neuropathy‡ | 25% | 20% | 1% | 1% | <1% | 0% |
| Dyspnea | 7% | 3% | 2% | 2% | 1% | 0% |
| Alopecia | 12% | 12% | ≤ 1% | 1% | 0% | 0% |
| * None of the reported toxicities were influenced by age.
Grade based on modified criteria from the National Cancer Institute. † Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy. ‡Incidence of paresthesia plus hypesthesia. |
||||||
Hematologic: Granulocytopenia is the major dose-limiting toxicity with NAVELBINE (vinorelbine tartrate) . Dose adjustments are required for hematologic toxicity and hepatic insufficiency (see DOSAGE AND ADMINISTRATION). Granulocytopenia was generally reversible and not cumulative over time. Granulocyte nadirs occurred 7 to 10 days after the dose, with granulocyte recovery usually within the following 7 to 14 days. Granulocytopenia resulted in hospitalizations for fever and/or sepsis in 8% of patients. Septic deaths occurred in approximately 1% of patients. Prophylactic hematologic growth factors have not been routinely used with NAVELBINE (vinorelbine tartrate) . If medically necessary, growth factors may be administered at recommended doses no earlier than 24 hours after the administration of cytotoxic chemotherapy. Growth factors should not be administered in the period 24 hours before the administration of chemotherapy. Whole blood and/or packed red blood cells were administered to 18% of patients who received NAVELBINE (vinorelbine tartrate) .
Neurologic: Loss of deep tendon reflexes occurred in less than 5% of patients. The development of severe peripheral neuropathy was infrequent (1%) and generally reversible.
Skin: Like other antirancer vinca alkaloids, NAVELBINE (vinorelbine tartrate) is a moderate vesicant. Injection site reactions, including erythema, pain at injection site, and vein discoloration, occurred in approximately one third of patients; 5% were severe. Chemical phlebitis along the vein proximal to the site of injection was reported in 10% of patients.
Gastrointestinal: Prophylactic administration of antiemetics was not routine in patients treated with single-agent NAVELBINE (vinorelbine tartrate) . Due to the low incidence of severe nausea and vomiting with single-agent NAVELBINE (vinorelbine tartrate) , the use of serotonin antagonists is generally not required.
Hepatic: Transient elevations of liver enzymes were reported without clinical symptoms.
Cardiovascular: Chest pain was reported in 5% of patients. Most reports of chest pain were in patients who had either a history of cardiovascular disease or tumor within the chest. There have been rare reports of myocardial infarction.
Pulmonary: Shortness of breath was reported in 3% of patients; it was severe in 2% (see WARNINGS). Interstitial pulmonary changes were documented.
Other: Fatigue occurred in 27% of patients. It was usually mild or moderate but tended to increase with cumulative dosing.
Other toxicities that have been reported in less than 5% of patients include jaw pain, myalgia, arthralgia, and rash. Hemorrhagic cystitis and the syndrome of inappropriate ADH secretion were each reported in < 1% of patients.
Combination Use: Adverse events for combination use are summarized in Tables 3 and 4.
NAVELBINE (vinorelbine tartrate) in Combination with Cisplatin
NAVELBINE (vinorelbine tartrate) plus Cisplatin versus Single-Agent Cisplatin (Table 3): Myelosuppression was the predominant toxicity in patients receiving combination therapy, Grade 3 and 4 granulocytopenia of 82% compared to 5% in the single-agent cisplatin arm. Fever and/or sepsis related to granulocytopenia occurred in 11% of patients on NAVELBINE (vinorelbine tartrate) and cisplatin compared to 0% on the cisplatin arm. Four patients on the combination died of granulocytopenia-related sepsis. During this study, the use of granulocyte colony-stimulating factor ([G-CSF] filgrastim) was permitted, but not mandated, after the first course of treatment for patients who experienced Grade 3 or 4 granulocytopenia (x1,000 cells/mm3) or in those who developed neutropenic fever between cycles of chemotherapy. Beginning 24 hours after completion of chemotherapy, G-CSF was started at a dose of 5 mcg/kg per day and continued until the total granulocyte count was > 1,000 cells/mm3/ on 2 successive determinations. G-CSF was not administered on the day of treatment. Grade 3 and 4 anemia occurred more frequently in the combination arm compared to control, 24% vs. 8%, respectively. Thrombocytopenia occurred in 6% of patients treated with NAVELBINE (vinorelbine tartrate) plus cisplatin compared to 2% of patients treated with cisplatin. The incidence of severe non-hematologic toxicity was similar among the patients in both treatment groups. Patients receiving NAVELBINE (vinorelbine tartrate) plus cisplatin compared to single-agent cisplatin experienced more Grade 3 and/or 4 peripheral numbness (2% vs. < 1%), phlebitis/thrombosis/embolism (3% vs. < 1%), and infection (6% vs. < 1%). Grade 3-4 constipation and/or ileus occurred in 3% of patients treated with combination therapy and in 1% of patients treated with cisplatin. Seven deaths were reported on the combination arm; 2 were related to cardiac ischemia, 1 massive cerebrovascular accident, 1 multisystem failure due to an overdose of NAVELBINE (vinorelbine tartrate) , and 3 from febrile neutropenia. One death, secondary to respiratory infection unrelated to granulocytopenia, occurred with single-agent cisplatin.
NAVELBINE (vinorelbine tartrate) plus Cisplatin versus Vindesine plus Cisplatin versus Single-Agent Vinorelbine (Table 4): Myelosuppression, specifically Grade 3 and 4 granulocytopenia, was significantly greater with the combination of NAVELBINE (vinorelbine tartrate) plus cisplatin (79%) than with either single-agent NAVELBINE (vinorelbine tartrate) (53%) or vindesine plus cisplatin (48%), P < 0.0001. Hospitalization due to documented sepsis occurred in 4.4% of patients treated with NAVELBINE (vinorelbine tartrate) plus cisplatin: 2% of patients treated with vindesine and cisplatin, and 4% of patients treated with single-agent NAVELBINE (vinorelbine tartrate) . Grade 3 and 4 thrombocytopenia was infrequent in patients receiving combination chemotherapy and no events were reported with single-agent NAVELBINE (vinorelbine tartrate) . The incidence of Grade 3 and/or 4 nausea and vomiting, alopecia, and renal toxicity were reported more frequently in the cisplatin-containing combinations compared to single-agent NAVELBINE (vinorelbine tartrate) . Severe local reactions occurred in 2% of patients treated with combinations containing NAVELBINE (vinorelbine tartrate) ; none were observed in the vindesine plus cisplatin arm. Grade 3 and 4 neurotoxicity was significantly more frequent in patients receiving vindesine plus cisplatin (17%) compared to NAVELBINE (vinorelbine tartrate) plus cisplatin (7%) and single-agent vinorelbine (9%) (P < 0.005). Cisplatin did not appear to increase the incidence of neurotoxicity observed with single-agent NAVELBINE (vinorelbine tartrate) .
Table 3: Selected Adverse Events From a Comparative Trial
of NAVELBINE (vinorelbine tartrate) plus Cisplatin versus Single-Agent Cisplatin*
| Adverse Event | NAVELBINE (vinorelbine tartrate) 25 mg/m2 plus Cisplatin 100 mg/m2
(n=212) |
Cisplatin 100 mg/m2 (n=210) |
||||
| All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 | |
| Bone Marrow | ||||||
| Granulocytopenia | 89% | 22% | 60% | 26% | 4% | 1% |
| Anemia | 88% | 21% | 3% | 72% | 7% | <1% |
| Leukopenia | 88% | 39% | 19% | 31% | <1% | 0% |
| Thrombocytopenia | 29% | 4% | 1% | 21% | 1% | <1% |
| Febrile neutropenia | N/A | N/A | 11% | N/A | N/A | 0% |
| Hepatic | ||||||
| Elevated transaminase | 1% | 0% | 0% | <1% | <1% | 0% |
| Renal | ||||||
| Elevated creatinine | 37% | 2% | 2% | 28% | 4% | <1% |
| Non-Laboratory | ||||||
| Malaise/fatigue/lethargy | 67% | 12% | 0% | 49% | 8% | 0% |
| Vomiting | 60% | 7% | 6% | 60% | 10% | 4% |
| Nausea | 58% | 14% | 0% | 57% | 12% | 0% |
| Anorexia | 46% | 0% | 0% | 37% | 0% | 0% |
| Constipation | 35% | 3% | 0% | 16% | 1% | 0% |
| Alopecia | 34% | 0% | 0% | 14% | 0% | 0% |
| Weight loss | 34% | 1% | 0% | 21% | <1% | 0% |
| Fever without infection | 20% | 2% | 0% | 4% | 0% | 0% |
| Hearing | 18% | 4% | 0% | 18% | 3% | <1% |
| Local (injection site reactions) | 17% | <1% | 0% | 1% | 0% | 0% |
| Diarrhea | 17% | 2% | <1% | 11% | 1% | <1% |
| Paresthesias | 17% | <1% | 0% | 10% | <1% | 0% |
| Taste alterations | 17% | 0% | 0% | 15% | 0% | 0% |
| Peripheral numbness | 11% | 2% | 0% | 7% | <1% | 0% |
| Myalgia/arthralgia | 12% | <1% | 0% | 3% | <1% | 0% |
| Phlebitis/thrombosis/embolism | 10% | 3% | 0% | <1% | 0% | <1% |
| Weakness | 12% | 2% | <1% | 7% | 2% | 0% |
| Dizziness/vertigo | 9% | <1% | 0% | 3% | <1% | 0% |
| Infection | 11% | 5% | <1% | <1% | <1% | 0% |
| Respiratory infection | 10% | 4% | <1% | 3% | 3% | 0% |
| * Graded according to the standard SWOG criteria. | ||||||
Table 4: Selected Adverse Events From a Comparative Trial
of NAVELBINE (vinorelbine tartrate) Plus Cisplatin versus Vindesine Plus Cisplatin versus Single-Agent
NAVELBINE (vinorelbine tartrate) *
| NAVELBINE/Cisplatin† | Vindesine/Cisplatin‡ | NAVELBINE§ | |||||||
| Adverse Event | All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 | All Grades | Grade 3 | Grade 4 |
| Bone Marrow | |||||||||
| Neutropenia | 95% | 20% | 58% | 79% | 26% | 22% | 85% | 25% | 28% |
| Leukopenia | 94% | 40% | 17% | 82% | 24% | 3% | 83% | 26% | 6% |
| Thrombocytopenia | 15% | 3% | 1% | 10% | 3% | 0.5% | 3% | 0% | 0% |
| Febrile neutropenia | N/A | N/A | 4% | N/A | N/A | 2% | N/A | N/A | 4% |
| Hepatic | |||||||||
| Elevated bilirubin | 6% | N/A | N/A | 5% | NIA | N/A | 5% | N/A | N/A |
| Renal | |||||||||
| Elevated creatinine | 46% | N/A | N/A | 37% | N/A | N/A | 13% | N/A | N/A |
| Non-Laboratory | |||||||||
| Nausea/vomiting | 74% | 27% | 3% | 72% | 24% | 1% | 31% | 1% | 1% |
| Alopecia | 51% | 7% | 0.5% | 56% | 14% | 0% | 30% | 2% | 0% |
| Ototoxicity | 10% | 1% | 1% | 14% | 1% | 0% | 1% | 0% | 0% |
| Local reactions | 17% | 2% | 0.5% | 7% | 0% | 0% | 22% | 2% | 0% |
| Diarrhea | 25% | 1.5% | 0% | 24% | 1% | 0% | 12% | 0% | 0.5% |
| Neurotoxicity ¶ | 44% | 7% | 0% | 58% | 16% | 1% | 44% | 8% | 0.5% |
| * Grade based on criteria from the World Health Organization (WHO). † n=194 to 207; all patients receiving NAVELBINE (vinorelbine tartrate) /cisplatin with laboratory and non-laboratory data. ‡n=173 to 192; all patients receiving vindesine/cisplatin with laboratory and non-laboratory data. § n=165 to 201; all patients receiving NAVELBINE (vinorelbine tartrate) with laboratory and non-laboratory data. Categorical toxicity grade not specified. ¶ Neurotoxicity includes peripheral neuropathy and constipation. |
|||||||||
Observed During Clinical Practice: In addition to the adverse events reported from clinical trials, the following events have been identified during post-approval use of NAVELBINE (vinorelbine tartrate) . Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to NAVELBINE (vinorelbine tartrate) .
Body as a Whole: Systemic allergic reactions reported as anaphylaxis, pruritus, urticaria, and angioedema; flushing; and radiation recall events such as dermatitis and esophagitis (see PRECAUTIONS) have been reported.
Hematologic: Thromboembolic events, including pulmonary embolus and deep venous thrombosis, have been reported primarily in seriously ill and debilitated patients with known predisposing risk factors for these events.
Neurologic: Peripheral neurotoxicities such as, but not limited to, muscle weakness and disturbance of gait; have been observed in patients with and without prior symptoms. There may be increased potential for neurotoxicity in patients with pre-existing neuropathy, regardless of etiology, who receive NAVELBINE (vinorelbine tartrate) . Vestibular and auditory deficits have been observed with NAVELBINE (vinorelbine tartrate) , usually when used in combination with cisplatin.
Skin:Injection site reactions, including localized rash and urticaria, blister formation, and skin sloughing have been observed in clinical practice. Some of these reactions may be delayed in appearance.
Gastrointestinal: Dysphagia, mucositis, and pancreatitis have been reported.
Cardiovascular: Hypertension, hypotension, vasodilation, tachycardia, and pulmonary edema have been reported.
Pulmonary: Pneumonia has been reported.
Musculoskeletal:Headache has been reported, with and without other musculoskeletal aches and pains.
Other: Pain in tumor-containing tissue, back pain, and abdominal pain have been reported. Electrolyte abnormalities, including hyponatremia with or without the syndrome of inappropriate ADH secretion, have been reported in seriously ill and debilitated patients.
Combination Use: Patients with prior exposure to paclitaxel and who have demonstrated neuropathy should he monitored closely for new or worsening neuropathy. Patients who have experienced neuropathy with previous drug regimens should be monitored for symptoms of neuropathy while receiving NAVELBINE (vinorelbine tartrate) . NAVELBINE (vinorelbine tartrate) may result in radiosensitizing effects with prior or concomitant radiation therapy (see PRECAUTIONS).
DRUG INTERACTIONS
Acute pulmonary reactions have been reported with NAVELBINE (vinorelbine tartrate) and other anticancer vinca alkaloids used in conjunction with mitomycin. Although the pharmacokinetics of vinorelbine are not influenced by the concurrent administration of cisplatin, the incidence of granulocytopenia with NAVELBINE (vinorelbine tartrate) used in combination with cisplatin is significantly higher than with single-agent NAVELBINE (vinorelbine tartrate) . Patients who receive NAVELBINE (vinorelbine tartrate) and paclitaxel, either concomitantly or sequentially, should be monitored for signs and symptoms of neuropathy. Administration of NAVELBINE (vinorelbine tartrate) to patients with prior or concomitant radiation therapy may result in radio sensitizing effects. Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP3A subfamily, or in patients with hepatic dysfunction. Concurrent administration of vinorelbine tartrate with an inhibitor of this metabolic pathway may cause an earlier onset and/or an increased severity of side effects.
Last reviewed on RxList: 12/17/2008
This monograph has been modified to include the generic and brand name in many instances.
Next: Drug Description
Additional Navelbine Information
Navelbine - User Reviews
Navelbine User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Navelbine sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.
From WebMD
Navelbine
Health Resources
Related Supplements
Use it Now
Find it Now
Pill Identifier on RxList
- quick,
easy,
concise
Find a Local Pharmacy
- including
24 hour
pharmacies
Updated & New
RxList does not provide medical advice, diagnosis or treatment.